C4X Discovery Holdings plc announces that it has received a milestone payment of 3 million from Sanofi under the IL-17A Inhibitor programme license agreement entered into in April 2021. Under the terms of the deal, C4XD is entitled to up to a total of 414 million in upfront, pre-clinical, development, regulatory and commercialisation milestone payments plus royalties on future net sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12 GBX | +27.32% | +40.35% | +33.33% |
01:53pm | C4X Discovery Set for Friday Delisting from London Bourse's AIM | MT |
Apr. 15 | C4X Discovery shareholders approve of taking firm private | AN |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+33.33% | 29.55M | |
+0.74% | 43.84B | |
+5.86% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+5.83% | 25.53B | |
-25.01% | 18.18B | |
-3.25% | 12.29B | |
+25.90% | 12.29B | |
+6.69% | 11.15B |
- Stock Market
- Equities
- C4XD Stock
- News C4X Discovery Holdings plc
- C4X Discovery Holdings plcReceives Sanofi Milestone Payment